Back to top
more

Acorda Therapeutics (ACOR)

(Delayed Data from NSDQ)

$2.46 USD

2.46
116,889

-0.15 (-5.75%)

Updated Dec 3, 2021 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.42%
2Buy19.05%
3Hold10.68%
4Sell6.41%
5Strong Sell3.08%
S&P50011.42%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (155 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of -9.57% and 6.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Acorda Therapeutics (ACOR) Report Negative Q2 Earnings? What You Should Know

Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of 3.15% and 30.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About Acorda (ACOR) Rating Upgrade to Strong Buy

Acorda (ACOR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

J&J (JNJ) Q1 Earnings Top, COVID-19 Vaccine Brings $100M Sales

J&J (JNJ) beats first-quarter 2021 estimates for both earnings and sales. It boosts quarterly dividend by 5%.

QIAGEN's (QGEN) NeuMoDx Multiplex Test Receives FDA EUA

QIAGEN's (QGEN) new NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test strengthens the company's portfolio in PCR testing, while becoming a crucial diagnostic tool for the flu season and the pandemic.

Tandem (TNDM) Grows on Abbott, Dexcom Pacts Amid COVID-19 Woes

Tandem Diabetes (TNDM) is expects t:sport to be a major growth catalyst for 2022.

Illumina's (ILMN) Expanded NIPT Coverage Study Outcome Favorable

Illumina's (ILMN) coverage for pregnant women under the age of 35 will provide access of NIPT to thousands of women with minimal financial impact.

Vertex (VRTX) Type I Diabetes Candidate Clinical Study Begins

Vertex (VRTX) begins early-stage clinical study on cellular therapy, VX-880 for type-I diabetes. FDA also grants Fast Track status to the candidate.

Has Acorda Therapeutics (ACOR) Outpaced Other Medical Stocks This Year?

Is (ACOR) Outperforming Other Medical Stocks This Year?

Illumina (ILMN) NGS-Based Platform Approved for Use in Russia

Illumina and R-Pharm's in-vitro diagnostics platform registration will drive the expansion of Next Generation Sequencing-based clinical diagnostics across Russia.

QIAGEN (QGEN) Unveils Digital Platform for Syndromic Testing

QIAGEN's (QGEN) QIAsphere cloud-based platform will enhance QIAstat-Dx's potential by offering remote services round the clock to improve testing continuity.

Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of -68.92% and 12.24%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Encompass Health (EHC) Ties Up for Better Homehealth Care

Encompass Health (EHC) forms partnership with Right at Home for value-based care models, which in turn, are expected to improve health outcomes.

    QIAGEN (QGEN) Launches QIAcube Connect MDx Platform Globally

    QIAGEN's (QGEN) QIAcube Connect MDx platform can be used with more than 140 standard protocols and it ensures complete consistency of the purification of multiple sample types.

    Medtronic's (MDT) HVAD Pump Kit Recall Classified as Class I

    The latest back-to-back incidents will, undoubtedly, create a major drag in Medtronic's (MDT) VAD performance.

    Novavax (NVAX) Loss Widens in Q4, Revenues Top Estimates

    Novavax's (NVAX) fourth-quarter 2020 loss is wider than estimates. Sales beat the same.

    Puma (PBYI) Q4 Loss Wider Than Expected, Nerlynx Sales Fall

    Puma Biotech (PBYI) reports wider-than-expected fourth-quarter loss while sales beat estimates.

    BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull

    BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.

    Bayer's (BAYRY) Q4 Earnings Match Estimates, Sales Miss

    Bayer (BAYRY) reports in-line earnings and misses sales estimates in the fourth quarter of 2020.

    Horizon's (HZNP) Shares Rise on Q4 Earnings & Sales Beat

    Horizon (HZNP) beats earnings and sales estimates in the fourth quarter of 2020.

    Acorda Therapeutics (ACOR) Sees Hammer Chart Pattern: Time to Buy?

    Acorda Therapeutics (ACOR) has been struggling lately, but the selling pressure may be coming to an end soon.

    Encompass Health (EHC) Unveils Plans to Expand in Maryland

    Encompass Health's (EHC) plans to construct a hospital is indicative of the company's efforts to offer improved healthcare services in southern Maryland.

    Seagen (SGEN), Astellas Submit 2 sBLAs to FDA for Urothelial Cancer

    Seagen (SGEN) and Astellas Pharma announced completion of submissions of two sBLAs to the FDA for Padcev in patients with locally advanced or metastatic urothelial carcinoma.

    bluebird (BLUE) Down on Suspension of Sickle Cell Disease Studies

    bluebird (BLUE) temporarily suspends two studies of LentiGlobin gene therapy in SCD because of reported Suspected Unexpected Serious Adverse Reactions of acute myeloid leukemia.